Navigation Links
Metastatic bone disease patients can walk in Lazarus' footsteps
Date:3/9/2009

SAN DIEGO, Calif. (March 9, 2009)Osteoplastya highly effective minimally invasive procedure to treat the painful effects of metastatic bone disease by injecting bone cement to support weakened bonesprovides immediate and substantial pain relief, often presenting individuals who are suffering terribly with the miraculous so-called "Lazarus effect," according to researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting. Interventional radiologists often couple osteoplasty with heat or cold treatments to kill tumor nerves, if needed.

"The immediate good clinical results observed in our patients should encourage more widespread application of this palliative interventional radiology treatment," said Giovanni C. Anselmetti, M.D., interventional radiologist at the Institute for Cancer Research and Treatment in Turin, Italy. "A patient's quality of life can be severely affected when they have metastatic bone disease. Normal daily activities can become difficult when the metastases become painful, and many patients report that their sleep patterns change, appetite diminishes and the need to take pain relief medications increases," he noted. "Osteoplasty is not a first-line treatment. It is a highly effective minimally invasive procedure that provides pain relief for patients not responding to conventional pain medication treatments," he said. "Metastatic bone disease patientswho have no other options, who are in pain, who have short life expectancies and who have dismal quality of lifeshould be referred to interventional radiologists for osteoplasty treatment. Interventional radiologists can improve the quality of life for patients who have very large metastases and who are going to die because of their primary cancers," added Anselmetti.

Metastatic bone disease is a painful condition that can develop in conjunction with cancers of the breast, bladder, kidney, lung or other organs. It occurs when cancer cells at an original site metastasize or travel to the bone. These metastases can become widespread throughout the skeletal system. Some bone metastases become painful because the tumor eats away at the bone (ostelolysis), creating holes that make the bone thin and weak. As the bones are replaced with tumor, nerve endings in and around the bone send pain signals to the brain and the bone loses its functional strength. If left untreated, bone metastases can eventually cause the bone to fracture and seriously affect a patient's quality of life. Each year, about 100,000 cases of bone metastasis are reported in the United States.

In treating cancer patients with painful bone metastases, interventional radiologists may also use radiofrequency ablation (RFA) or cryoablation. These treatments use heat or cold to desensitize the bone by killing the nerve endings in the vicinity of the metastasis. Once the nerve endings are dead, interventional radiologists can perform osteoplasty. Osteoplasty involves the injection of semi-liquid bone cement (in this case, polymethyl-methacrylate or PMMA) into a bone lesion under constant and precise visual monitoring by CT or digital fluoroscopy imaging. The technique is similar to vertebroplasty, an interventional radiology treatment that has been used extensively in the spine to treat the pain of compression fractures.

In the study, the average pain intensity score for patients based on the 11-point visual analog scale dropped significantly from 8.8 +/1.4 to 1.8 +/2.1 within 24 hours of osteoplasty, said Anselmetti. "These patients experienced immediate and substantial pain relief. They did not require pain medication during the time of follow-up, and there were no clinically significant complications," said Anselmetti. Of 81 patients (59 women, 12 men), 64 (79 percent) were able to stop taking narcotic drugs for their pain, and 43 (53 percent) could stop taking other pain medication. In this study, pelvic, femur, sacrum, ribs, homerus, scapula, tibia, pubis and knee bones were treated.

In one case, Anselmetti recounted, a 79-year-old Roman Catholic nun had severe pain and was bedridden because of cancerous osteolytic lesions (thyroid cancer metastases) located deep in her pelvispreviously treated unsuccessfully with chemotherapy and radiotherapy. She underwent osteoplasty and experienced significant relief of pain and was able to walk two hours after the procedure. "This is the Lazarus effect," said Anselmetti, referring to the term often used to connote an apparent restoration to life, with Lazarus being the subject of the miracle recounted in the New Testament in which Jesus raises him from the dead. The nun, like other patients, was able to be discharged from the hospital on the same day.

"I cannot emphasize enough how important it is to provide relief to patients who are dying from their cancers. In most cases we can provide pain relief, restore function for them to do daily activities and help them to stay ambulatory," said Anselmetti. He noted that osteoplasty provided effective pain regression for individuals with both painful bone metastases and benign lytic lesions that didn't respond to conventional analgesic treatment.

Bones are the third most common location where cancer cells spread and metastasize. Bone metastases occur when cancer cells gain access to the blood stream, reach the bone marrow, begin to multiply and then grow new blood vessels to obtain oxygen and foodwhich in turn causes the cancer cells to grow more and spread. For the most part, the goal of treating bone tumors is not curative, but rather palliative by reducing pain, preventing additional bone destruction and improving function.


'/>"/>

Contact: Maryann Verrillo
mverrillo@SIRweb.org
703-460-5572
Society of Interventional Radiology
Source:Eurekalert

Related biology news :

1. $2.7 million awarded for metastatic colon cancer research
2. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
3. Metastatic movements in 3-D
4. Antioxidant overload may underlie a heritable human disease
5. Gender, coupled with diabetes, affects vascular disease development
6. Study links cat disease to flame retardants in furniture and to pet food
7. Humans fostering forest-destroying disease
8. Emerging (disease) markets
9. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
10. Clemson chemists discover new way antioxidants fight debilitating diseases
11. Finding that 1-in-a-billion that could lead to disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology: